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One out of three pediatric sepsis deaths in high income countries occur in previously 
healthy children. Primary immunodeficiencies (PIDs) have been postulated to under-
lie fulminant sepsis, but this concept remains to be confirmed in clinical practice. 
Pseudomonas aeruginosa (P. aeruginosa) is a common bacterium mostly associated 
with health care-related infections in immunocompromised individuals. However, in rare 
cases, it can cause sepsis in previously healthy children. We used exome sequencing and 
bioinformatic analysis to systematically search for genetic factors underpinning severe 
P. aeruginosa infection in the pediatric population. We collected blood samples from 11 
previously healthy children, with no family history of immunodeficiency, who presented 
with severe sepsis due to community-acquired P. aeruginosa bacteremia. Genomic DNA 
was extracted from blood or tissue samples obtained intravitam or postmortem. We 
obtained high-coverage exome sequencing data and searched for rare loss-of-function 
variants. After rigorous filtrations, 12 potentially causal variants were identified. Two out 
of eight (25%) fatal cases were found to carry novel pathogenic variants in PID genes, 
including BTK and DNMT3B. This study demonstrates that exome sequencing allows 
to identify rare, deleterious human genetic variants responsible for fulminant sepsis in 
apparently healthy children. Diagnosing PIDs in such patients is of high relevance to 
survivors and affected families. We propose that unusually severe and fatal sepsis cases 
in previously healthy children should be considered for exome/genome sequencing to 
search for underlying PIDs.
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inTrODUcTiOn
Despite worldwide reduction in childhood mortality, sepsis 
remains one of the leading causes of childhood deaths. Importantly, 
35–50% of pediatric sepsis deaths occur in previously healthy chil-
dren (1–3). These children often develop non-specific symptoms 
suggestive of a viral respiratory infection, followed by sudden 
deterioration and rapid progression to shock and multisystem 
organ failure. In addition to pathogen virulence factors, such as 
streptococcal Toxic Shock Toxin (4), rare genetic variants caus-
ing a primary immunodeficiency (PID) may underlie fulminant 
sepsis. Such variants have high effect sizes and are usually kept at 
low frequencies in the population due to purifying selection (5, 
6). Previous studies searching for PID in children with bacterial 
sepsis were limited to conventional immunological testing (5). 
Using high-throughput sequencing studies on individuals with 
extreme phenotypes, who are most likely to be informative from 
a genetic point of view, has been demonstrated to be very power-
ful in Mendelian diseases but has not been reported in patient 
cohorts with invasive bacterial infections (6).
Pseudomonas aeruginosa (P. aeruginosa) is an aerobic Gram-
negative bacterium commonly found in environment. This 
opportunistic pathogen causes invasive infections in immuno-
suppressed and hospitalized patients and represents a major 
cause of health care-related infections. In contrast, sepsis due to 
community-acquired P. aeruginosa is extremely rare in appar-
ently healthy children, and carries very high mortality (7, 8), and 
may be the first manifestation of an underlying PID. Indeed, a few 
case reports have already described the identification of PIDs in 
children with P. aeruginosa sepsis (9, 10). Here, we used exome 
sequencing and bioinformatic analysis to identify genetic variants 
conferring extreme susceptibility to P. aeruginosa in a cohort of 
11 previously healthy children.
MaTerials anD MeThODs
Patients
Children below 60 months with community-acquired blood-cul-
ture positive P. aeruginosa sepsis were eligible. Children with any 
comorbidities (prematurity, congenital malformations, previous 
surgery, immunosuppression, known immunodeficiency, and 
chronic diseases) and children who had been exposed to broad-
spectrum intravenous antibiotics were excluded. This study was 
carried out in accordance with the recommendations of the ethics 
committees of participating centers (Kantonale Ethikkommission 
Bern, KEK Ref Nr 029/11, Bern, Switzerland; Mater Health 
Services HREC13/MHS/4, Brisbane, QLD, Australia). Parents/
guardians of all included patients gave written informed consent 
in accordance with the Declaration of Helsinki. Patients were 
recruited prospectively and retrospectively in hospital databases 
and infectious diseases networks. Whenever possible, DNA was 
also collected from the parents.
Dna extraction and exome sequencing
Genomic DNA was extracted from whole blood (N = 8), frozen 
skin biopsy or lymphatic tissue (N = 2), or paraffin-fixed histol-
ogy slides (N =  1). Exome sequencing libraries were prepared 
using Agilent SureSelect (V5, 50.4 Mb). Cluster generation was 
performed using Illumina TruSeq PE Cluster Kit v5 reagents. 
Libraries were sequenced as 100  bp long, paired-end reads on 
Illumina HiSeq 2500 using TruSeq SBS Kit v5 reagents.
short read alignment
Sequencing reads were processed using CASAVA v1.82. Reads 
were aligned to the human reference genome hg19 using BWA 
(11, 12) v0.6.2. PCR duplicates were removed using Picard 1.27-1 
(http://picard.sourceforge.net/).
Variant calling
We used genome analysis toolkit (GATK) (13, 14) version 3.1-1 
to call single nucleotide variants (SNVs) and small insertion and 
deletions (indels) from duplicate-marked bam files. We used 
HaplotypeCaller for multi-sample variant calling on all samples 
followed by GATK best practice to call the variants and included 
only variants that were flagged as PASS by GATK in subsequent 
analysis.
Variant effect Prediction
We used SnpEff (15) version 4.1B to predict the functional impact 
of variants. As variants can have several predicted effects, we only 
considered the most severe effect for each variant. The effects 
in decreasing order of severity are frameshift and in-frame for 
indels and stop-gain, splice site-disrupting, non-synonymous, 
synonymous, intronic, UTR, non-coding exon, and intergenic 
for SNVs. Variants were annotated as putative loss-of-function 
(LoF) if they were stop-gain or splice site-disrupting SNVs or 
frameshift indels mapping to the first 95% of coding region, or 
larger deletions removing either the first exon or more than 50% 
of the protein-coding sequence of the affected transcript.
Variant Frequency estimation
We checked the minor allele frequency (MAF) of all previously 
described variants in the following datasets: the NHLBI exome 
sequencing project (ESP, N  =  6503) (16), the 1000 genomes 
project phase 2 (1KG, N =  876) (17) and the UK10K project 
(UK10K, N = 3621) (18), the Exome Aggregation Consortium 
database (ExAC, N =  60,706) (19), and a set of 533 in-house 
control exomes.
identification of Potentially causal 
Variants in Parent–child Trios
We restricted analyses to non-synonymous and LoF exonic vari-
ants with MAF <1% in ESP, 1KG, UK10K, ExAC, and in-house 
control exomes. We analyzed each family separately assuming 
autosomal recessive, autosomal dominant, and X-linked reces-
sive inheritance models. Only variants with >10× coverage in 
both the parents and the offspring were included in the de novo 
analysis. We assumed full penetrance for the potentially causal 
variants and given the fatality of the phenotype did not consider 
a mutation as potentially causal if it was present in the parents, 
any of the abovementioned databases or in the in-house control 
exomes in the same zygosity form (i.e., heterozygous or homozy-
gous) as in our patients.
TaBle 1 | new PiD genes discovered since the latest report of iUis in 2015 till april 2016.
Official gene name Mutation inh. Phenotype study population reference
STAT4 Missense AD Kaposi sarcoma One consanguineous pedigree (21)
MAP3K9 Non-sense AR Susceptibility to severe bacterial infection, Pseudomonas septic shock One consanguineous pedigree (22)
IRF3 Missense AD Herpes simplex encephalitis 16 sporadic cases (23)
AR, autosomal recessive; AD, autosomal dominant; Inh., inheritance; GOF, gain-of-function.
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identification of Potentially causal 
Variants in individual Patients
We restricted analyses to non-synonymous and LoF exonic 
variants with MAF <1% in ESP, 1KG, UK10K, ExAC, and in-
house control exomes. We analyzed each individual separately 
assuming autosomal recessive and X-linked recessive inheritance 
models. We assumed full penetrance for the potentially causal 
variants and given the fatality of the phenotype did not consider 
a mutation as potentially causal if it was present in any of the 
abovementioned databases or in the in-house control exomes in 
the same zygosity form (i.e., heterozygous or homozygous) as in 
our patients.
Targeted search in Primary 
immunodeficiency genes
We ran a targeted search for rare (MAF <1%), non-synonymous, 
and LoF variants in a list of 252 known PID genes. This list 
includes known genes in 50 PID syndromes compiled by The 
International Union of Immunological Societies (IUIS) Expert 
Committee in 2015 (20) and 3 newly published PID genes since 
the latest release of IUIS till April 2016 (Table 1).
gene-annotation enrichment analysis
We used the database for annotation, visualization, and integrated 
discovery (DAVID) (24, 25) v6.7 with default options and highest 
classification stringency for functional annotation clustering of 
PID genes carrying rare, non-synonymous variants. We used 
hypergeometric test for assessing the significance of gene enrich-
ment results.
c9 reconstitution experiment
Serum of a patient heterozygous for a complement C9 variant 
was diluted with GVB++ in a series starting at 1:10 to 1:640 in 
1:2 steps. The same was done with a serum pool as a control. 
This pool consisted of serum from over 300 healthy donors. Forty 
microliters of these dilutions were pipetted in duplo in a round-
bottom 96-wells plate. To these wells, 40 μl of GVB++ was added 
to the samples and the blanc, to the positive control 40 μl of 1.7% 
saponin was added (100% lysis). Ten microliters of purified C9 
(Quidel) or GVB++ were added (end conc 50 μg/ml). Next, in 
all wells, 150 μl of EA’s were added. EA’s are sheep erythrocytes 
(Hatunalab, Sweden) coated with an optimal dose of Amboceptor 
(Rabbit-anti-Sheep erythrocyte; Dade Behring) brought to a 
concentration of 0.25 × 108 cells/ml. This was incubated for 1 h at 
37°C while agitating. After incubation, the plate was centrifuged 
for 5 min at 2000 rpm. Fifty microliters of each supernatant were 
pipetted to a flat-bottom 96-wells plate and diluted with 150 μl 
GVB++. Extinction was measured at 415 nm using a spectropho-
tometer. The percentage of lysis was calculated as follows:
 
average of  sample duplo average blanc
average ave
−
−
( ) /
   100% rage blanc( )





×100.
 
GVB++ buffer consisted of 2  mM 5,5 di-ethylbarbituurzuur 
(Genfarma), 1.15 mM Na 5,5 di-ethylbarbituraat (Bufa), 96 mM 
NaCl (Merck), 0.5  mM CaCl (Merck), and 0.18  mM MgCl2 
(Merck).
resUlTs
clinical Presentation
We identified 11 previously healthy children with community-
acquired P. aeruginosa bacteremia from whom DNA could be 
obtained. Child–parent DNA trios were available in seven affected 
families. The presenting age ranged from 6 months to 4 years, and 
7/11 (64%) of patients were male (Table 2). All patients had never 
been admitted to hospital or exposed to intravenous antibiot-
ics prior to presenting with P. aeruginosa sepsis. Nine patients 
had developed respiratory symptoms within 72 h of leading to 
hospital admission, one presented with Ecthyma gangrenosum 
(Figure  1), and eight (73%) died. Three children died in the 
emergency department shortly after presentation, and all deaths 
occurred within 48 h of hospital admission. Postmortem exami-
nation reports were available in seven cases. In four, P. aeruginosa 
grew in high quantities from nasal and oral swabs, tracheal secre-
tions, and lungs. Viral co-infections were found in five deceased 
patients, including human herpes virus-6, parainfluenza virus-3, 
human metapneumovirus, respiratory syncytial virus, and vari-
cella virus. One surviving patient presented with acute abdomen, 
and P. aeruginosa bacteremia was thought to result from intra-
abdominal perforation. Another surviving patient was diagnosed 
with urosepsis and P. aeruginosa grew in urine and blood. The 
third surviving patient presented with recurrent parainfectious 
neutropenia. Six patients received aminoglycosides and/or anti-
Pseudomonas beta-lactam antibiotics during sepsis, including all 
three survivors.
exome sequencing and  
short read alignment
For each sample, 95% of reads passing filtering criteria were 
unique (not marked as duplicate); 97% of unique reads could be 
aligned to the human reference genome hg19. The mean on-bait 
coverage was 66×, with 95% of target bases achieving at least 10× 
coverage and 76% achieving at least 30× coverage (Table S1 in 
FigUre 1 | ecthyma gangrenosum, a highly suggestive rapidly 
progressive purpuric skin lesion seen in a minority of children with P. 
aeruginosa bacteremia, is shown in one of the study patients (with 
permission from parents).
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Supplementary Material). In 118 of the PID genes, at least one 
exon had an average coverage of <2×. Further investigation of 
these low-coverage intervals showed that the majority of them are 
overlapping with untranslated regions (UTRs).
Variant calling and Variant annotation
A total of 115,604 SNVs and 10,814 indels passed GATK quality 
control, including 28,795 synonymous variants, 28,284 non-
synonymous variants, 713 in-frame indels, 660 frameshift indels, 
283 stop-gained, and 151 splice-site variants (Tables S2 and S3 in 
Supplementary Material).
Variant analysis
Thirty-eight rare, non-synonymous coding variants (MAF <1%) 
were observed in the 11 patients after testing for different inherit-
ance models (Table 3), among which 12 were never seen in the 
same zygosity form (heterozygous or homozygous) in publicly 
available databases (Table 4). In addition to the above 38 vari-
ants, we performed a targeted search for rare, non-synonymous 
coding variants in 252 previously known PID genes and found 76 
variants in 61 genes (Table 5). Functional classification of these 
61 genes using DAVID highlighted the complement pathway as 
the most enriched cluster (DAVID enrichment score: 15.73). In 
total, 14 of the 28 complement pathway genes present in the list of 
252 known PID genes carried at least one rare, non-synonymous 
coding variant in our cohort (hypergeometric probability: 
p(x > 14) = 0.003).
In one patient (patient S4) who died of fulminant septic shock, 
we identified a novel single-base insertion on the X chromosome 
(C  >  CT, chromosome 20, position 100617191) leading to a 
frameshift in the Bruton agammaglobulinemia tyrosine kinase 
(BTK) gene. Other than a middle ear infection during infancy, 
the previous history, growth, development, and vaccination his-
tory of the patient had been unremarkable. Taqman genotyping 
TaBle 3 | 38 rare (MaF <1% in esP, 1KP, UK10K, exac, and in-house controls) non-synonymous and putative loF variants found in our 11 patients 
using different inheritance models (see Materials and Methods for details).
Patient inheritance chr Position effect gene exac MaF%
S4 AR 2 202957848 Missense AC079354.1 0.33
S4 XL X 99920649 Missense SRPX2 0
S4 XL X 100617192 Frameshift BTK 0
S10 AD 13 112721975 Missense, de novo SOX1 0
S10 AR 10 71906005 Missense TYSND1 0.37
S10 XL X 9864517 Missense SHROOM2 0
S10 XL X 53575033 Missense HUWE1 0
S10 XL X 70824419 Missense ACRC 0
S13 AR 19 55879673 Missense IL11 0.01
S13 AR 19 56423631 Missense NLRP13 0.01
S13 AR 19 57132935 Missense ZNF71 0
S13 AR 19 57840274 Missense ZNF543 0.01
S13 AR 20 31765978 Missense BPIFA2 0.02
S13 AR 20 31393172 In-frame indel DNMT3B 0
S13 XL X 53222222 Missense KDM5C 1.41E−03
S13 XL X 101619974 Missense NXF2B 0
S14 AR 3 119526149 Missense NR1I2 0.14
S14 AR 3 19977627 Splice site disrupting EFHB 0.29
S14 AR 17 1265305 splice site disrupting YWHAE 0.03
S14 AR 19 39362359 splice site disrupting RINL 0.15
S15 XL X 27998602 Missense DCAF8L1 0.01
S15 XL X 68382133 Missense PJA1 0
S15 XL X 101097713 Splice site disrupting NXF5 0
S17 AR 1 6662288 Missense KLHL21 0.16
S17 CH 1 155015918 Missense DCST1 0.26
155015948 Missense 0
S17 CH 10 112572308 Missense RBM20 0.01
112590912 Missense 0.02
S17 CH 17 76420087 Missense DNAH17 0.01
76522984 Missense 0.03
S17 XL X 109561080 Missense AMMECR1 0
S20 CH 19 41035017 Missense SPTBN4 0.08
41025445 Missense, de novo 0
S23 CH 16 4934707 Missense PPL 8.23E−04
4940241 Missense 0.05
S23 CH 17 28405505 Missense EFCAB5 0.05
28380755 Non-sense 0.01
S23 XL X 19364694 Missense PDHA1 0.29
Chr, chromosome; AR, autosomal recessive; AD, autosomal dominant, XL, X-linked; CH, compound heterozygous.
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and clinical genetic testing confirmed presence of mutation in 
the deceased patient and revealed a de novo occurrence in the 
mother, while other family members were healthy. BTK plays a 
crucial role in B-cell development. Postmortem serological test-
ing confirmed the absence of immunoglobulins, consistent with 
BTK LoF: IgG <  1.3  g/l (4.22–11.9); IgA <  0.2  g/l (0.2–1.58); 
IgM < 0.2g/l (0.48–1.9).
A novel homozygous deletion spanning 6  bp on chromo-
some 20 (ACTCGAG > A, X chromosome, position 31393171) 
was observed in a 2-year-old boy with consanguineous parents 
(patient S13), leading to an in-frame deletion in a conserved 
region of the catalytic domain of the DNMT3B gene. Previously 
described missense mutations in the same protein domain are 
known to cause immunodeficiency-centromeric instability-facial 
anomalies (ICF) syndrome (26), a rare disease characterized by 
variable immunodeficiency and recurrent infections with mild 
facial abnormalities. The fatal septicemia was preceded by uncom-
plicated varicella, and the patient had a history of recurrent mild 
respiratory and upper airway infections that had been attributed 
to poor health conditions. The patient had normal T and B cell 
counts but reduced immunoglobulin levels, consistent with ICF 
syndrome: IgG 0.16 g/l (4.22–11.9); IgA <0.06 g/l (0.2–1.58); IgM 
0.05 g/l (0.48–1.9).
We also observed a rare, known (MAF =  0.001 in ExAC) 
heterozygous stop-gain variant in the complement C9, on chro-
mosome 5 (G > T, chromosome 5, position 39342214) in a male 
patient (patient S15) with severe Pseudomonas septicemia and 
recurrent parainfectious neutropenia. The patient survived with-
out sequelae. Complement reconstitution assay with classical or 
terminal pathway proteins (C1–C9) showed normal lytic activity 
TaBle 4 | Potentially causal variants (see Materials and Methods for details) identified in 6 of the 11 previously healthy children with  
community-acquired Pseudomonas aeruginosa septicemia.
inheritance Patient chr. Position gene effect exac MaF (%)
AR S14 7 142562052 EPHB6 In-frame indel 0
S13 20 31393172 DNMT3B In-frame indel 0
AD S20 19 41025445 SPTBN4 Missense, de novo 0
S10 13 112721975 SOX1 Missense, de novo 0
XL S4 X 100617192 BTK Frameshift indel 0
S10 X 27998602 DCAF8L1 Missense 1.14E−03
S10 X 9864517 SHROOM2 Missense 0
S10 X 53575033 HUWE1 Missense 0
S10 X 70824419 ACRC Missense 0
S15 X 68382133 PJA1 Missense 0
S15 X 101097713 NXF5 Splice site disrupting 0
S15 X 109561080 AMMECR1 Missense 0
Chr, chromosome; MAF, minor allele frequency; AR, autosomal recessive; AD, autosomal dominant, XL, X-linked.
6
Asgari et al. Exome Sequencing in Septic Children
Frontiers in Immunology | www.frontiersin.org September 2016 | Volume 7 | Article 357
(Figure 2), suggesting that this variant is unlikely to be causal to 
increased susceptibility to P. aeruginosa.
DiscUssiOn
We studied P. aeruginosa sepsis in previously healthy children 
as a model disease defining an extreme phenotype of fulminant 
sepsis. Fulminant sepsis in children is associated with high 
mortality, and the majority of deaths occur within hours of 
presentation (27). The disease burden is highest in children 
under 5 years of age (3, 7). We hypothesized that rare genetic 
variants with high effect sizes could explain life-threatening 
susceptibility to P. aeruginosa in children without known risk 
factors or comorbidities. Mendelian disorders of immunity have 
previously been shown to result in phenotypes with unusual 
susceptibility to bacterial infection, such as pseudomonal and 
pneumococcal infections in patients with IRAK-4 deficiency 
(10, 28). We used exome sequencing to explore the genetic 
cause of susceptibility to P. aeruginosa in a carefully selected 
group of previously healthy children with no familial history 
of immunodeficiency, who developed community-acquired P. 
aeruginosa septicemia. By systematic search for fully penetrant, 
rare, non-synonymous, and LoF variants in exonic regions, we 
identified 12 potentially causal variants including two novel 
variants in known PID genes: X-linked agammaglobulinemia 
due to a novel BTK mutation and ICF immunodeficiency 
syndrome due to a novel DNMT3B mutation. In addition, we 
performed a targeted search for rare, non-synonymous, and 
LoF variants in known PID genes and observed an enrichment 
of such variants among genes that are part of the complement 
pathway. One patient carried a heterozygous, stop-gain vari-
ant in the C9 gene, which has been associated with recurrent 
meningitis (29, 30). However, functional testing of patient 
samples showed normal lytic activity, demonstrating the need 
for strict validation of potentially causal mutations, even in 
genes with plausible biological links to the study phenotype. 
Variants conferring life-threatening susceptibility to common 
infections in children below reproductive age are subjected to 
strong purifying selection and will therefore only be found at 
very low frequencies (31–33). Out of the 12 potentially causal 
variants described in this study, 11 were novel and 1 was a 
hemizygous variant present in 1 individual (in heterozygous 
form) in ExAC.
Previous case reports describing P. aeruginosa sepsis in 
children with known PIDs, such as Wiskott–Aldrich syn-
drome, X-linked agammaglobulinemia, cyclic neutropenia, 
and IRAK-4/MyD-88 deficiency (8, 10, 22, 34), were based on 
conventional, candidate–gene-driven immunological testing. 
Ecthyma gangrenosum is present in a minority of patients and 
has been described as the presenting sign of an underlying PID, 
such as cyclic neutropenia, chronic granulomatous disease, or 
hypogammaglobulinemia (35–37). The range of PID types iden-
tified in these previous reports indicates that multiple distinct 
genetic defects have to be considered when investigating such 
clinical presentations. Importantly, classic PID screening may 
fail to identify new mutations in known PID genes (38) and 
will miss causal mutations in genes without an established link 
with PIDs. Failure to diagnose rare underlying PID in a child 
presenting with sepsis may result in potentially devastating 
consequences for survivors, undiagnosed siblings, and their 
families. High-throughput sequencing, in particular exome 
sequencing, has proved highly successful in the clinical diagnosis 
of suspected monogenic conditions in the pediatric population 
(39–41). This was recently illustrated by Record et al., who used 
exome sequencing in a girl with P. aeruginosa sepsis and found a 
homozygous LoF mutation in MAP3K9 (MKL1), a gene that was 
not known to cause PID (22).
A strength of the present cohort is that the case definition 
required significant growth of community-acquired P. aerugi-
nosa in blood culture in previously healthy children presenting 
with signs and symptoms of sepsis, thereby constituting an 
extreme phenotype. The majority of children included in this 
study presented with fulminant sepsis and septic shock due to 
Pseudomonas sepsis. In the cases where postmortem examina-
tions were performed, extensive growth of P. aeruginosa was 
found in several tissues, suggesting overwhelming bacterial 
infection. In agreement with other studies, we observed that sev-
eral sepsis patients had viral co-infections (3). The role of viral 
TaBle 5 | 76 rare (exac MaF <1%) non-synonymous and putative loF variants found in known 252 PiD genes in our 11 patients.
Patient chr. Position effect Type gene exac MaF%
S1 11 108098576 Missense Het ATM 0.74
S10 9 340168 Missense Het DOCK8 0
S10 11 4104647 Missense Het STIM1 8.25E−04
S10 11 108117787 Missense Het ATM 0.13
S10 5 41155088 Missense Het *C6 0.69
S13 20 31393172 In-frame indel Hom DNMT3B 0
S13 8 100844596 Splice site disrupt Het VPS13B 0.43
S13 2 231036831 Missense Het SP110 4.12E−03
S13 5 77334907 Missense Het AP3B1 0.08
S13 6 31915584 Missense Het *CFB 0.1
S13 11 6637588 Missense Het TPP1 0.18
S13 11 2407334 Missense Het CD81 0.56
S13 5 147475388 Missense Het SPINK5 0.65
S13 5 35876300 Missense Het IL7R 0.24
S13 12 110034347 Missense Hom MVK 0.13
S13 1 196799796 Missense Hom *CFHR1 0.14
S13 10 6063567 Missense Het IL2RA 0.88
S14 8 100654621 Missense Het VPS13B 0.02
S14 12 110017618 Missense Het MVK 0.07
S14 8 100861113 Missense Het VPS13B 0.06
S14 1 11094908 Missense Het *MASP2 0.08
S14 15 91337505 Missense Het BLM 0.1
S14 8 48733399 Missense Het PRKDC 0.09
S14 6 32798457 Missense Het TAP2 0.49
S14 1 949422 Missense Het ISG15 0.16
S14 11 108129778 Missense Het ATM 0.21
S14 11 108123551 Missense Het ATM 0.29
S14 3 196198925 Missense Het RNF168 0.2
S14 8 90982691 Missense Het NBN 0.26
S14 9 139840153 Missense Het *C8G 0.46
S14 4 187004767 Missense Het TLR3 0.3
S14 6 32800427 Missense Het TAP2 0.61
S14 1 196684855 Missense Het *CFH 0.5
S14 10 73103969 Missense Het SLC29A3 0.54
S14 9 123751873 Missense Het *C5 0.61
S14 9 123737145 Missense Het *C5 0.91
S14 1 196715063 Missense Het *CFH 0.97
S14 20 62324328 Missense Het RTEL1 0.98
S15 5 39342214 Non-sense Het *C9 0.1
S15 2 47277182 Missense Het TTC7A 0.2
S15 2 47273468 Missense Het TTC7A 0.21
S15 10 97983635 Missense Het BLNK 0.55
S15 11 108138003 Missense Het ATM 0.91
S16 16 27460420 Missense Het IL21R 0.03
S16 9 139264888 Missense Het CARD9 0.35
S16 5 158750329 Missense Het IL12B 0.65
S17 17 73826517 Missense Het UNC13D 2.25E−03
S17 1 949431 Missense Het ISG15 4.17E−03
S17 16 50745960 Missense Het NOD2 0.03
S17 5 1268697 Missense Het TERT 0.09
S17 17 26875685 Missense Het UNC119 0.01
S17 17 76120792 Missense Het TMC6 0.65
S17 15 91295110 Missense Hom BLM 0.86
S17 8 42177163 Missense Het IKBKB 0.89
S20 11 118898444 Missense Het SLC37A4 0
S20 12 122064747 Missense Het ORAI1 0
S20 22 36662063 Missense Het APOL1 0.01
S20 1 22965341 Missense Het *C1QA 0.04
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(Continued)
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FigUre 2 | Titration of serum with/without c9 in a study patient with a heterozygous stop-gain variant in the C9 gene.
Patient chr. Position effect Type gene exac MaF%
S20 11 108119823 Missense Het ATM 0.22
S20 4 151242409 Missense Het LRBA 0.46
S23 1 207646266 Missense Het *CR2 3.30E−03
S23 1 235896980 Missense Het LYST 0.02
S23 1 154247666 Missense Het HAhet 0.03
S23 1 183536358 Missense Het NCF2 0.23
S23 6 137540425 Missense Het IFNGR1 0.14
S23 22 31007023 Missense Het TCN2 0.27
S23 1 207925595 Missense Het *CD46 0.5
S23 5 40945397 Missense Het *C7 0.95
S4 X 100617192 Frameshift indel Het BTK 0
S4 1 151316324 Missense Het RFX5 0.88
S7 12 133263886 Missense Het POLE 0.14
S7 19 18170874 Missense Het IL12RB1 0.17
S7 X 77150892 Missense Het MAGT1 0.29
S7 16 81957106 Missense Het PLCG2 0.13
S7 4 110667485 Missense Het *CFI 0.34
S7 5 41155088 Missense Het *C6 0.69
The genes marked by the asterisk are involved in complement activation.
Chr, chromosome; hom, homozygous; het, heterozygous.
TaBle 5 | continued
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co-infections in the pathogenesis of childhood bacterial sepsis 
is poorly understood and may include facilitated bacterial inva-
sion due to respiratory epithelial disruption and increased host 
susceptibility during viremia (42). Immunological investigations 
in children presenting with fulminant sepsis can be extremely 
challenging, as severe leukopenia, coagulopathy, multi-organ 
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failure, and fluid resuscitation often lead to severe alterations 
of cell counts, immunoglobulin levels, and complement levels. 
In addition, a proportion of patients die prior admission to an 
intensive care unit, or present with out-of-hospital cardiac arrest 
or sudden infant death syndrome (43). To date, there are no 
widely accepted guidelines to inform pediatricians, emergency 
and intensive care physicians, and pathologists about indications 
for specific immunological investigations in previously healthy 
children presenting with fulminant or fatal sepsis (44). Given the 
high fatality in our cohort, with several cases recruited consider-
able time after death of the patient, our study highlights the value 
of performing exome sequencing in this population using blood 
or tissue containing DNA. However, the lack of viable host cells 
in deceased patients may represent a major limitation toward 
functional validation of potentially causal variants. Elucidating 
the role of these variants in novel genes that may confer a PID 
phenotype will therefore require independent validation in other 
patients or cohorts.
While it is well known that PIDs can be responsible for severe 
bacterial infections, little is known about the proportion of chil-
dren with invasive infections suffering from PID (5). In our cohort, 
defects in known PID genes were found in 25% of fatal cases. This 
is comparable to a recent study using exome sequencing in 50 
patients with common variable immunodeficiency where exome 
sequencing identified disease-causing mutations in 30% of cases 
(45). While non-genetic factors, including variation in pathogen 
virulence and secondary neutropenia, may be responsible for 
the remaining cases, we cannot rule out that mutations in genes 
not previously associated with PID are at least partially involved. 
Sequencing of additional family members, sequencing of more 
cases with the same phenotype, and functional characterization 
of new candidate genes and variants will be required to identify 
such genetic factors. Furthermore, whole-genome sequencing is 
needed to explore the non-coding variants, large structural vari-
ants, and also exonic variants that are not be well-covered using 
exome sequencing.
In conclusion, this study provides proof of concept that exome 
sequencing allows the identification of rare genetic variants 
responsible for fulminant sepsis in children in whom immunode-
ficiency had not been previously suspected. Given the decreasing 
cost of exome and genome sequencing (39, 40, 46), we propose 
considering host DNA sequencing as a possible diagnostic pro-
cedure for apparently healthy children presenting with unusually 
severe or fatal sepsis.
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